A phase I/II clinical trial of two mRNA vaccines (CV-9103 and CV-9104) for prostate cancer targeting four prostate-specific antigens (STEAP, PSCA, PSMA, and PSA) produced good results (15). Here, KLK3 is linked to prostate carcinoma.